PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 4069 (113th)

Ensuring Patient Access and Effective Drug Enforcement Act of 2013

openUnited States· United States Congress· EN

Introduced

18 February 2014

Last action

7 April 2014 · Committee

Status

Subcommittee Hearings Held.

Sponsors

Tom Marino, Marsha Blackburn, Sen. Gardner, Cory [R-CO], Doug Collins, Rep. Amodei, Mark E. [R-NV-2], Rep. Griffin, Tim [R-AR-2], Brett Guthrie, George Holding, Billy Long, Shelley Capito, Rep. Ellmers, Renee L. [R-NC-2], Bill Johnson, Robert Latta, JOE BARTON, Mike Coffman

Subjects

Discovery layer

Source updated

12 August 2025

Summary

Ensuring Patient Access and Effective Drug Enforcement Act of 2013 - Amends the Controlled Substances Act to require registrants to manufacture, distribute, or dispense controlled substances to obtain a criminal background check on, and perform drug testing on, each employee with access to facility areas where controlled substances are stored. Requires such background checks to be obtained when such an employee is hired and periodically thereafter, but not more frequently than every two years. Authorizes registration suspension or revocation and a $10,000 penalty for failing to comply with such requirements. Requires the Attorney General, before revoking or suspending a registration under such Act, to: (1) provide the registrant notice of the grounds for doing so, and where such grounds consist of a legal violation, a specific citation to such law; (2) give the registrant an opportunity to submit a corrective action plan within a reasonable time period; and (3) determine whether, in light of the plan, revocation or suspension proceedings should be discontinued or deferred or additional changes need to be made in such plan. Establishes the Combating Prescription Drug Abuse Working Group to: (1) report on federal initiatives to reduce prescription drug diversion and abuse, (2) identify gaps and opportunities to ensure the safe use of prescription drugs with the potential for diversion and abuse, (3) examine recommendations to transfer one or more controlled substances from schedule III to schedule II to evaluate the effectiveness of such a transfer in reducing diversion and abuse and any effect of such a transfer on access to prescription drugs for legitimate medical purposes, (4) make recommendations on specific ways to reduce the diversion and abuse of prescription drugs, and (5) report on its efforts to prevent or reduce prescription drug diversion and abuse to ensure that patients continue to have access to medications.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 18 February 2014

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  2. 18 February 2014

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 18 February 2014

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 21 February 2014

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  5. 20 March 2014

    Referred

    Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

    Source: Committee

  6. 7 April 2014

    Committee

    Subcommittee Hearings Held.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.